Publications – Gustav Ullenhag

Publications in DiVA

Publications in PubMed

Selected publications:

  1. Irenaeus S*, Nielsen D*, Ellmark P, Yachnin Y, Deronic A, Nilsson A, Norlén P, Veitonmäki N, Wennersten C and Ullenhag G. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013 in advanced solid malignancies. International journal of cancer, 2019, 145(5):1189-1199. * shared first position.
  2. Irenaeus S, Maleka A, Wenthe J, Svensson E, Krause J, Sundin A, Ahlström H, Tötterman T, Loskog A och Ullenhag G. Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients. Oncotarget, 8(45):78573-78587.
  3. Valachis A and Ullenhag G. Discrepancy in BRAF status among patients with metastaticmalignant melanoma: a meta-analysis. European Journal of Cancer, 2017, 81, 06-115. 
  4. Loskog A*, Maleka A*, Mangsbo S, Svensson E, Lundberg C, Nilsson A, Krause J, Agnarsdóttir M, Sundin A, Ahlström H, Tötterman TH#, Ullenhag G#. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer. 2016, 114(8):872-80. *shared first position, # shared last position.
  5. Maleka A, Enblad G, Sjörs G, Lindqvist A, Ullenhag GJ. Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol. 2013, (11):e192-3.
  6. Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res. 2007, 13(17):5070-5.
  7. Ullenhag GJ, Spendlove I, Watson NF, Indar AA, Dube M, Robins RA, Maxwell-Armstrong C, Scholefield JH, Durrant LG. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Cancer Res. 2006, 12(24):7389-96.
  8. Ullenhag GJ, Frödin JE, Jeddi-Tehrani M, Strigård K, Eriksson E, Samanci A, Choudhury A, Nilsson B, Rossmann ED, Mosolits S, Mellstedt H. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res. 2004, 10(10):3273-81. (Utsedd till “Feature Article”).
  9. Ullenhag GJ, Frödin JE, Mosolits S, Kiaii S, Hassan M, Bonnet MC, Moingeon P, Mellstedt H, Rabbani H. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res. 2003, 9(7):2447-56.
  10. Ullenhag GJ, Frödin JE, Strigård K, Mellstedt H, Magnusson CG. Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen. Cancer Res. 2002, 62(5):1364-9. One of the most cited of all cancer papers in the short term, according to citation index.